期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌吉西他滨化疗耐药相关酶 被引量：1

Enyzmes of gemcitabine resistance in non-small cell lung cancer chemotherapy
原文传递
导出
摘要 吉西他滨是治疗非小细胞肺癌一线方案的主要药物之一，但肿瘤对其原发或继发耐药常导致该药无效。研究表明核糖核苷酸还原酶、核苷转运蛋白、细胞质-5’-核苷酸酶-Ⅱ、c—Jun氨基末端激酶及微囊蛋白-1与吉西他滨耐药相关。 Gemcitabine is one of main first- line drugs in non- small cell lung cancer chemotherapy, but primary or secondary drug resistance often leads to be invalid. Studies indicate that ribonucleotide reductase, nueleoside transporters, Cytosolic 5 ＇ - nucleotidase Ⅱ , c-Jun NH2- terminal kinase and caveolin- 1 are associated with gemcitabine resistance.
作者 胡南均(综述) 干惠珠(审校) 卢振霞(审校)
机构地区 吉林大学中日联谊医院血液肿瘤科
出处 《国际肿瘤学杂志》 CAS 2009年第8期604-606,共3页 Journal of International Oncology
关键词 吉西他滨 癌 非小细胞肺 耐药 药物疗法 Gemcitabine Carcinoma, non- small- cell lung Drug resistance Drug therapy
分类号 R734.2 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献15

  • 1Bepler G, Kusmartseva I, Sharma S, et al. RRMI modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-sniall cell lung cancer. J Clin Oncol, 2006, 24(29) :4731-4737.
  • 2Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res, 2004, 10(4) :1318-1325.
  • 3Ceppi P, Volante M, Novello S, et al. ERCC1 and RRMI gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 2006, 17(12) :1818-1825.
  • 4Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRMI and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE, 2008, 3 ( 11 ) : e3695.
  • 5Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCCI in lung cancer. N Engl J Med, 2007, 356 (8) : 800- 808.
  • 6Achiwa H, Oguri T, Sato S, et al. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cance. Cancer Sci, 2004, 95(9) :753-757.
  • 7Oguri T, Achiwa H, Muramatsu H, et al. The absence of human equilibrative nucleoside transporterl expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung caneer. Cancer Lett, 2007, 256(1 ):112-119.
  • 8Seve P, Mackey JR, Isaac S, et al. CN- H expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer, 2005,49(3) :363-370.
  • 9Galmarini CM, Cros E, Thomas X, et al. The prognostic value of CN - Ⅱ and CN- Ⅲenzymes in adult acute myeloid leukemia. Haematologica, 2005, 90(12) :1669-1701.
  • 10Suzuki K, Sugawara T, Oyake T, et al. Clinical signifi cance of high-Kin 5 '-nucleotidase (cN-Ⅱ ) mRNA expression in high-risk myelodysplastic syndrome. Leuk Res, 2007, 31 ( 10 ) : 1343-1349.

同被引文献18

  • 1Azzoli CG,Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage 1V non-small-cell lung cancer [ J ]. J Clin Oncol, 2009,27 ( 36 ) : 6251-6266.
  • 2Judde J G, Rebucci M, Vogt N, et al. Gefitinib and Chemotherapy Combination Studies in Five Novel Human Non Small Cell Lung Cancer Xenografts. Evidence Linking Egfr Signaling to Gefitinib Antitumor Response[ J]. Int J Cancer,2007 (120) : 1579-1590.
  • 3Li J,Liang X, and Yang X, Ursolic Acid Inhibits Growth and Induces Apoptosis in Gemcitabine-Resistant Human Pancreatic Cancer Via the Jnk and Pi3 k/Akt/Nf-Kappab Pathways [ J ]. Oncol Rep, 2012 ( 28 ) : 501-510.
  • 4ZhengC,Jiao X, Jiang Y, et al. Erkl/2 Activity Contributes to Gemcitabine Resistance in Pancreatic Cancer Cells[ J]. J Int Med Res, 2013(41 ) :300-306.
  • 5Teraishi F,Zhang L, Guo W, et al. Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells[ J ]. FEBS Lett,2005,579 (29) :6681-6687.
  • 6Vicent S, Garayoa M, Lepez-Pieazo JM, et al. Mitogen-aetivated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients [ J ]. Clin Cancer Res,2004,10( 11 ) :3639-3649.
  • 7Lin HH,Chen JH. Huang CC, et al. Apoptotic effect of 3,4-dihydroxy- benzoic acid on human gastric carcinoma ceils involving JNK/p38 MAPK signaling activation [ J ]. Int J Cancer, 2007, 120 ( 11 ): 2306-2316.
  • 8Yan HQ,Huang XB, Ke SZ, et al. , Interleukin 6 Augments Lung Cancer Chemotherapeutic Resistance Via Ataxia-Telangiectasia Mutated/Nf-Kappab Pathway Activation [ J ]. Cancer Sci, 2014 ( 105 ) : 1220-1227.
  • 9Kim YJ, Choi WI, Jean BN, et al., Stereospecific Effects of Ginsenoside 20-Rg3 Inhibits Tgf-Betal-lnduced Epithelial-Mesenchymal Transition and Suppresses Lung Cancer Migration, Invasion and Anoikis Resistance [ J ]. Toxicology, 2014 ( 322 ) :23 -33.
  • 10Chen TJ,Zhou YF, Ning JJ, et al. , Nbm-T-Bmx-Os01, an Osthole Derivative, Sensitizes Human Lung Cancer Asg9 Cells to Cisplatin through Ampk-Dependent Inhibition of Erk and Akt Pathway [ J ]. Cell Physiol Biochem,2015 (36) :893-906.

引证文献1

二级引证文献2

国际肿瘤学杂志
2009年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部